Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

85.31
BATS BZX Real-Time Price
As of 11:08am ET
 +1.42 / +1.69%
Today’s Change
31.99
Today|||52-Week Range
91.77
+99.74%
Year-to-Date
Ultragenyx Pharmaceutical Inc. 2020 Q2 - Results - Earnings Call Presentation
Jul 31 / Seeking Alpha - Paid Partner Content
Ultragenyx Pharmaceutical Q2 2020 Earnings Preview
Jul 29 / Seeking Alpha - Paid Partner Content
Ultragenyx Pharmaceutical Inc (RARE) Q2 2020 Earnings Call Transcript
Jul 31 / MotleyFool.com - Paid Partner Content
Notable earnings after Thursday's close
Jul 29 / Seeking Alpha - Paid Partner Content
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2020 Results - Earnings Call Transcript
Jul 30 / Seeking Alpha - Paid Partner Content
European advisory group backs expanded use of Crysvita
Jul 24 / Seeking Alpha - Paid Partner Content
Ultragenyx Pharmaceutical EPS beats by $1.94, beats on revenue
Jul 30 / Seeking Alpha - Paid Partner Content
 

Today’s Trading

Previous close83.89
Today’s open84.18
Day’s range84.18 - 85.42
Volume818
Average volume (3 months)512,324
Market cap$5.1B
Data as of 11:08am ET, 08/13/2020

Growth & Valuation

Earnings growth (last year)-79.30%
Earnings growth (this year)+35.41%
Earnings growth (next 5 years)+86.06%
Revenue growth (last year)+101.41%
P/E ratioNM
Price/Sales23.30
Price/Book7.49

Competitors

 Today’s
change
Today’s
% change
UTHRUnited Therapeutics ...-0.44-0.40%
HCMHutchison China Medi...-2.04-5.99%
MYOKMyoKardia Inc-0.68-0.67%
GRFSGrifols SA+0.34+1.86%
Data as of 11:12am ET, 08/13/2020

Financials

Next reporting dateNovember 9, 2020
EPS forecast (this quarter)-$1.38
Annual revenue (last year)$103.7M
Annual profit (last year)-$402.7M
Net profit margin-388.31%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Novato, California

Forecasts